anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. 
     SUBSTANCE: method involves introducing 0.1-1% aqueous solution of photosensibilizer agent of porphyrin or hematoporphyrin series belonging to Photohem or Photophryne group at a dose of 2.5-5.0 mg/kg. After accomplishing enucleation, scanning laser radiation of muscle funnel cavity is carried out. Muscle funnel cavity tamponade is done with two implant components. The implant is manufactured from carbon felt impregnated with photosensibilizing gel based on hyaluronic acid viscoelastic from chealon, viscoate or hyatulon group. The gel has 0.1-1 % by mass of photosensibilizer of porphyrin or hematoporphyrin series belonging to Photohem or Photophryne group. The first implant component is placed at the beginning. Scanning laser radiation of muscle funnel cavity with the first implant component being arranged in it, is carried out during 2-4 min after 15-30 min long exposure away from light action. The second implant component is placed. Scanning laser radiation of muscle funnel cavity after 15-30 min long exposure away from light action is carried out in the same mode. Direct muscles are sutured. Soft tissues are sutured layer-by-layer. The postoperative space is drained. Laser light guide is introduced into cubital vein immediately after enucleation. Intravenous laser radiation treatment of blood is carried out during 10-45 min with total power of 20-50 mW. 
     EFFECT: enhanced effectiveness of treatment; excluded soft tissue deformity in orbital region; reduced implant rejection and carcinoma cells dissemination risk.
Sepsis is associated with brain injury and acute brain inflammation, which can potentially transition into chronic inflammation, triggering a cascade of inflammatory responses that may lead to neurological disorders. Minocycline, recognized for its potent anti-inflammatory properties, was investigated in this study for its protective effects against sepsis-induced brain injury. Adult male C57 mice pretreated with minocycline (12.5, 25, and 50 mg/kg) 3 days before sepsis induction. An intraperitoneal injection of 5 mg/kg LPS was used to induce sepsis. Spontaneous locomotor activity (SLA) and weight changes were assessed over several days post-sepsis to monitor the recovery of the mice. The expression of inflammatory mediators and oxidative stress markers was assessed 24 h post sepsis. Septic mice exhibited significant weight loss and impaired SLA. Initially, minocycline did not attenuate the severity of weight loss (1 day) or SLA (4 h post-sepsis), but it significantly accelerated the recovery of the mice in later days. Minocycline dose-dependently mitigated sepsis-induced brain inflammation and oxidative stress. Our findings demonstrate that pretreatment with minocycline has the potential to prevent brain tissue damage and accelerate recovery from sepsis in mice, suggesting that minocycline may serve as a promising therapeutic intervention to protect against sepsis-induced neurological complications.
Premedication: Pregabalin 50-150mg x2, IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Dexdmedetomidine 0.5-1mcg/kg, Lidocaine 1mg/kg, Propofol 2-3mg/kg, Ketamine 1-1.5mg/kg, Hyoscine 10mg, Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/kg, Magnesium sulphate 2.5-5g and Dexamethasone 8-16mg. Anesthesia maintenance: Desflurane set at \~1 MAC, Dexmedetomidine 0.2-1.2mcg/kg/h, Lidocaine 0.5-1mg/kg/h, Ketamine 0.3-0.5mg/kg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, and Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. ICU sedation: Dexmedetomidine + Lidocaine infusions, until removal of the ETT. Surgical ward: PCA pump with Ketamine, Lidocaine, Clonidine and Midazolam for the first 3 postoperative days. Additionally, Pregabalin 50mg per os x1 and 25mg x1, up to x2, Paracetamol 1g x3 +/- Dexketoprofen trometamol 50mg x2. Rescue therapy only: Tramadol 50-100mg.
A method of using a medical food to increase human fertility. This medical food consists of transfer factor, lactic acid generating bacteria, and glucans in appropriate combinations. The medical food, administered correctly, reduces cortisol levels. Progesterone increases as cortisol decreases, and progesterone is needed to support pregnancy and ovulation. Dosage amounts are adjusted for client weight. Typically, consumption of the medical food begins several days before planned conception.
Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins have lower toxicity than native IL-2 or Proleukin ?? IL-2, while maintaining or enhancing NK cell-mediated effects, and can be used in pharmaceutical compositions for use in treatment of cancer, and in stimulating the immune response.
A medical device and a method of implementing a cryptosystem on the medical device include storing a data structure on a memory component of the medical device. An encryption key is stored in the data structure. Usage data related to usage of the medical device is provided. The encryption key is read from the data structure. The usage data is encrypted with the read encryption key. The encryption key is eliminated such that the encryption key is no longer present in the medical device.
BACKGROUND: This study explored the performance of surgeons for predicting radiological sarcopenia as accessed by psoas cross-sectional area in patients with colorectal cancer (CRC).
METHODS: A cross-sectional study was carried out and a diagnostic accuracy strategy was applied using the radiologist team assessment as gold standard.
RESULTS: Cohort analysis of 45 consecutive patients found that 31.1% had sarcopenia. Correlation of Total Psoas Index between radiologists and surgeons was very strong for the Junior and strong for the Senior surgeon, with a strong correlation between the surgeons. By the simplistic criterion, agreement between radiologists and surgeons was substantial for both the Junior and Senior surgeons, with a moderate level between the surgeons. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of Junior surgeon were 92.9%, 83.9%, 72.2%, 96.3%, and 86.7%, respectively. The corresponding results for the Senior surgeon were 78.6%, 90.3%, 78.6%, 90.3%, and 86.7%, respectively. We found no major differences on agreement levels and performance of surgeons using the composite criterion.
CONCLUSIONS: Surgeons seem to be accurate for identifying radiological sarcopenia in patients with CRC. The simplistic criterion should be preferred since a composite criterion adds complexity without increasing accuracy or agreement levels.
Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Cognitive Remediation treatment twice weekly for 8 weeks (16 sessions).
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine, namely to a health assessment system. What is presented is a system which enables the average person to know their ranking by analyzing the principal component, where using the values of medical examination Dx, which are blood tests, as explanatory variables. Three principal component variables are obtained with peak values of the maximum discrepancies, the variables include a variable habits of energy consumption C1, a variable habit of power balance C2 and a variable habit of exercise C3. System includes: a data input section configured to input data of medical inspection values Dx, a design section configured to calculate corresponding variables of habits C1–C3 based on coefficients and a formula selected based on analysis of the principal component and a display section of the results, configured to display on the screen the ranking of the object among the data of a large number of people obtained in advance using the calculation section. Variables of habits C1–C3 include elements in 3 groups. State of health of the object is evaluated by obtaining in accordance with 3 variables of principal component C1–C3 ranging of object among data of a large number of people.EFFECT: group of inventions provides improved health assessment system.11 cl, 1 tbl, 19 dwg
A gel type cosmetic composition is provided to improve a moisturizing effect, maintain added pigments steadily in the gel type cosmetic composition and reduce a sticky feeling when users apply gel type cosmetics to their hair. A gel type cosmetic composition comprises a 5-20wt.pt. of silicone surfactant, 2-5wt.pt. of water, and a 5-30wt.pt. of ethanol. The silicone surfactant contains poly(dialkylsiloxane) which has branched polyoxyalkylene. The Polyoxyalkylene is selected from the group consisting of polyoxyethylene and polyoxypropylene. A ratio of polyoxyalkylene and poly(dialkylsiloxane) is 0.025-0.05 by weight. The polymerization mole number of the polyoxyalkylene is 10-27 moles. The gel type cosmetic composition additionally contains silicon oils.
Subjects will be treated with N-acetyl cysteine twice daily for seven days. Subject will complete a minimum of 30-day washout period before crossing over to take the placebo.
Psychological symptomatology and quality of life (QoL) have been studied in older people with HIV (PWH) and those with chronic obstructive pulmonary disease (COPD), respectively, but there is a dearth of studies in older PWH with COPD. Our study compared depressive symptoms, anxiety, and QoL between older PWH with and without COPD using data from an HIV clinic in Birmingham, Alabama, from January 2018 to February 2020. Data on depressive symptoms (Patient Health Questionnaire-9), anxiety (Patient Health Questionnaire-5 Anxiety), and QoL (EuroQoL-5 Dimension) were analyzed. Among 690 PWH aged 50 years or older, 102 individuals (14.8%) had COPD. Significant differences were found between the two groups in depressive symptoms and components of QoL (e.g., mobility, self-care, usual activities, and pain/discomfort), but not in anxiety and general health. Experiencing COPD may worsen depressive symptomatology and QoL in older PWH, highlighting the need for tailored health care and research for this population.
The invention relates to a medicine capable of supporting healthy energy and eliminating toxin, particularly a high-stability ultramicropowder agent capable of supporting healthy energy and eliminating toxin. The invention is characterized in that the ultramicropowder agent is prepared from the following components in parts by weight: 60 parts of radix isatidis, 60 parts of radix astragali, 30 parts of epimedium and 10-16 parts of rhubarb. The medicine is pulverized into ultramicropowder, and mixed with 13-17 parts of pentaerythritol ultramicropowder to obtain the ultramicropowder agent. The formula is improved: the conventional rhubarb for purging intense heat and eliminating toxin is added; and the ultramicropowder agent can not cause diarrhoea of animals, but has obvious curative effect on fever symptoms of the animals. The ultramicropowder agent is preferably a specific dispersing agent, thereby obviously prolonging the stable period of the product, preventing moisture absorption and lumping, prolonging the shelf life of the medicine, lowering the medicine cost and avoiding waste of resources. The formula is still simple, and still has the original functions of the powder capable of supporting healthy energy and eliminating toxin.
OBJECTIVE: The aim of this study was to conduct a comprehensive evaluation of the rehydration efficacy of QSBYD and elucidate its potential underlying mechanism.
DESIGN: 38 participants were randomly assigned to receive either QSBYD or placebo before and after exercise and heat-induced dehydration. Hydration indicators were measured over time. Blood tests assessed cellular anaerobic respiration metabolites, serum inflammatory markers, and coagulation markers. Perceptual measures of thirst, fatigue, and muscular soreness were also taken.
RESULTS: QSBYD consumption resulted in lower urine volume (Control vs. QSBYD: 260.83 ± 167.99 ml vs. 187.78 ± 141.34 ml) and smaller decrease in percentage of nude body weight change from baseline (Control vs. QSBYD: -0.52 ± 0.89% vs. -0.07 ± 0.52%). Although no significant differences in urine specific gravity, QSBYD resulted in reduced urine volume at 120 min, suggesting improved fluid retention. Furthermore, QSBYD resulted in lower levels of IL-1β (Control vs. QSBYD: 2.40 ± 0.68 vs. 1.33 ± 0.66 pg/mL), suggesting QSBYD may provide benefits beyond hydration.
CONCLUSION: Further investigation into the underlying mechanisms and long-term effects of QSBYD on hydration is warranted. QSBYD may be an effective alternative to commercial sports drinks in mitigating dehydration effects.
PURPOSE:To provide a method for producing a barium sulfate contrast medium solution without causing a change in coagulation and a rise in viscosity in the digestive tract. CONSTITUTION:Barium sulfate, as necessary, together with a well-known additive, is added to deionized water in an adequate amount (usually an amount so as to provide 50-200 wt./vol.%, preferably 100-200 wt./vol.% barium sulfate concentration), stirred and mixed to prepare a barium contrast medium solution. The deionized water is produced by mixing an extremely trace amount of, e.g. a substance capable of providing a transition state when a ferrous and ferric salt substance such as ferric chloride is mixed in an aqueous solution of a strong alkali and the valence transition is caused. Since the solution is excellent in suspension stability of the barium sulfate particles in the digestive tract, the barium sulfate particles enter fine parts of the digestive tract wall, especially the depth of the fine mucous membrane wall of the gastric wall and uniformly stick thereto. Thereby, the digestive tract can accurately radiographed.
PROBLEM TO BE SOLVED: To provide hydroxyapatite spherical particles useful as a packing material into the dental root canals of man or animals, a packing material into the tooth extraction cavity and a vital material, such as a residual ridge rebuilding material and the vital material using the same. SOLUTION: An aq. phosphoric acid soln. is added to a suspension contg. the hydroxyapatite spherical particles of 0.5 to 200 μm in average grain size and 8 to 12 in pH value, when 1 g spherical particles are added to 25 g water and the soln. is stirred, and 1 to 20 wt.% calcium hydroxide in such a manner that the pH value attains 9 to 12. Amorphous calcium phosphate is synthesized while the temp. of this suspension is controlled so as not to exceed 50 deg.C. The resulted amorphous calcium phosphate is then granulated and dried to once obtain the amorphous calcium phosphate spherical particles of 0.5 to 200 μm in the average grain size and, thereafter, the spherical particles are fired at 800 to 1300 deg.C, by which the hydroxyapatite particles having excellent osteogenetic capability are produced. These hydroxyapatite spherical particles are utilized as the vital material.
Patients receive durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
Clear cell sarcoma of soft tissue is a rare malignancy derived from neural crest cells that contain melanin and/or melanin precursors. Melanin is an important target for the diagnosis of clear cell sarcoma of soft tissue. 18F-PFPN, a highly specific melanin-targeting positron probe, has been proven to have excellent pharmacokinetic properties and good biological safety, and can sensitively detect tiny melanin-containing lesions. Therefore, 18F-PFPN PET imaging is expected to be used in diagnosing and staging clear cell sarcoma of soft tissue.

This study was designed as a prospective study to explore the diagnosis and staging value of 18F-PFPN PET in clear cell sarcoma of soft tissue. In this study, patients with clinically suspected or confirmed clear cell sarcoma of soft tissue will be recruited to undergo 18F-PFPN PET/MR imaging. PET/CT imaging will be performed in patients with contraindications to MR. The general information, clinical data, imaging data and histopathology results of patients will be collected. The efficiency of diagnosis and staging of 18F-PFPN was evaluated by comparing the gold standard pathological diagnosis and the general metabolic imaging agent 18F-FDG.
The present disclosure provides a system and a method for providing personalized and community-based recommendations. The system is configured with one or more primary sensors and a wearable device to monitor multiple health parameters from a user. The wearable device is configured with one or more secondary sensors to monitor additional health parameters from the user. Further, the system uses artificial intelligence (AI) to generate a personalized model or a digital twin based on the inputs from the one or more primary sensors and the wearable device. The generated personalized model continuously monitors the inputs and triggers an emergency service upon a significant variation in the inputs. Further, the system provides various micro services to facilitate personalized and community based recommendations. The system utilizes a blockchain network to generate smart contracts and reward the user based on the inputs from the digital twin model.
Patients who test positive will receive a call from the provider who conducted the test to notify them of the test result and provide standard-of-care counseling (e.g., health education, link them to resources). Index patients are entered into a COVID-19 patient registry in the Federally Qualified Health Center's electronic health record system (which also is linked to the clinic's COVID-19 dashboard) and monitored closely, with telemedicine follow-ups provided by skilled clinical staff every two-to-three days, and in-person follow-ups provided as needed.
BACKGROUND: Chromosome stability is crucial for homeostasis of pluripotent stem cells (PSCs) and early-stage embryonic development. Chromosomal defects may raise carcinogenic risks in regenerative medicine when using PSCs as original materials. However, the detailed mechanism regarding PSCs chromosome stability maintenance is not fully understood.
METHODS: Mouse embryonic stem cells (line D3) and human embryonic stem cells (line H9) were cultured under standard conditions. To confirm the loading of RetSat protein on mitotic chromosomes of PSCs, immunostaining was performed in PSCs spontaneous differentiation assay and iPSC reprogramming assay from mouse embryonic fibroblasts (MEFs), respectively. In addition, qPCR, immunoprecipitation, LC-MS/MS and immunoblotting were used to study the expression of RetSat, and interactions of RetSat with cohesin/condensin components. RNA sequencing and teratoma formation assay was conducted to evaluate the carcinogenic risk of mouse embryonic stem cells with RetSat deletion.
RESULTS: We reported a PSC high-expressing gene, RetSat, plays key roles in chromosome stabilization. We identified RetSat protein localizing onto mitotic chromosomes specifically in stemness positive cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). We found dramatic chromosome instability, e.g. chromosome bridging, lagging and interphase micronuclei in mouse and human ESCs when down regulating RetSat. RetSat knock-out mouse ESCs upregulated cancer associated gene pathways, and displayed higher tumorigenic capacities in teratoma formation assay. Mechanistically, we confirmed that RetSat interacts with cohesin/condensin components Smc1a and Nudcd2. RetSat deletion impaired the chromosome loading dosage of Smc1a, Smc3 and Nudcd2.
CONCLUSIONS: In summary, we reported RetSat to be a key stabilizer of chromosome condensation in pluripotent stem cells. This highlights the crucial roles of RetSat in early-stage embryonic development, and potential value of RetSat as an effective biomarker for assessing the quality of pluripotent stem cells.
Scavenger receptor type B (SR-BI) is a receptor that binds both native and altered lipoproteins. It was revealed to facilitate utilization of high-density lipoprotein HDL and significantly affect the reverse transport of cholesterol. Therefore, the objectives were to identify the possible role of the genetic variant rs4238001 in patients with myocardial infarction (MI) on serum lipid level, and how this variant could impact the response of rosuvastatin drug. The genotyping of the rs4238001 genetic polymorphism of the SR-B1 gene was performed in 300 participants, including 150 MI patients treated with 20mg/day/4 weeks of rosuvastatin and 150 healthy control using Taq man probes (FAM and VIC) by Real-time PCR technique. The concentrations of the lipid profile were evaluated. The significance of the anthropometric data was revealed in the ejection fraction and smoking status (p < 0.05) between groups. The lipid profile shows either significant differences between control and MI patients (pre-treatment) or between pre-and post-treatment of MI patients (p < 0.05), but not HDL-c (p > 0.05). The minor allele frequency MAF% of the T allele and TT genotype were more frequent in MI patients than in controls (P = 0.173; OR = 3.62; 95% CI = 0.74-17.64). CC genotype was found to be associated with response to rosuvastatin therapy with a change of % (29.08 ± 53.2; p = 0.021). In the Iraqi population, the rs4238001 polymorphism of the SR-B1 gene is associated with variations in serum lipids, and the CC genotype of the SNP is related to higher HDL-C in the lipid-lowering rosuvastatin response.
The present invention relates to a protein and a sugar binding protein resisting the activity of viruses of human acquired immune system syndrome, which comes from marine invertebrates (serpula lacrymans, serpulavermicularis or serpula rhizomorphs). The present invention more specifically relates to a protein with the activity for resisting the viruses of human acquired immune system syndrome in the process of cell fusion in the acute infection period and the chronic infection period of human acquired immune system syndrome, wherein the protein has an amino acid sequence shown in SEQ ID NO. 1. Indices of the sugar binding protein for resisting the viruses of human acquired immune system syndrome in cells outside bodies are approximately 200 times higher than those of AZT, and has no toxicity to C8166 cells of the T lymphocyte system of human beings. The sugar protein is expressed in saccharomycete by 15 amino acid sequences at an N terminal of the sugar binding protein by a molecular biology method. A structural analog of the present invention can become a potential medicine guiding compound resisting acquired immune deficiency syndrome.